The Newly Discovered Parkinson’s Disease Associated Finnish Mutation (A53E) Attenuates α-Synuclein Aggregation and Membrane Binding
Biochemistry2014Vol. 53(41), pp. 6419–6421
Citations Over TimeTop 10% of 2014 papers
Dhiman Ghosh, Shruti Sahay, Priyatosh Ranjan, Shimul Salot, Ganesh M. Mohite, Pradeep K. Singh, Saumya Dwivedi, Edmund Carvalho, Rinti Banerjee, Ashutosh Kumar, Samir K. Maji
Abstract
α-Synuclein (α-Syn) oligomerization and amyloid formation are associated with Parkinson's disease (PD) pathogenesis. Studying familial α-Syn mutants associated with early onset PD has therapeutic importance. Here we report the aggregation kinetics and other biophysical properties of a newly discovered PD associated Finnish mutation (A53E). Our in vitro study demonstrated that A53E attenuated α-Syn aggregation and amyloid formation without altering the major secondary structure and initial oligomerization tendency. Further, A53E showed reduced membrane binding affinity compared to A53T and WT. The present study would help to delineate the role of A53E mutation in early onset PD pathogenesis.
Related Papers
- → The role of α-synuclein in neurodegenerative diseases(2004)201 cited
- → The potential of zwitterionic nanoliposomes against neurotoxic alpha-synuclein aggregates in Parkinson's Disease(2018)43 cited
- → Diagnostic accuracy and predictors of alpha-synuclein accumulation in the gastrointestinal tract of Parkinson’s disease(2024)7 cited
- → O.026 Mice over-expressing wild-type human alpha-synuclein as tools for therapeutic discovery in Parkinson's disease(2009)
- More than a synuclein story: Dissecting determinants for alpha-synuclein aggregation and degradation in the Parkinson’s disease brain(2020)